&ot&uot Kate Stern REFERENCE: O-144 KATE STERN, Royal Women’s Hospital, Melbourne A potential new way of preserving ovarian function during chemotherapy for cancer could be treatment w
&ot&uot
Kate Stern
REFERENCE: O-144KATE STERN, Royal Women’s Hospital, MelbourneA potential new way of preserving ovarian function during chemotherapy for cancer could be treatment with an antagonist of gonadotropin-releasing hormone: GnRH. A pilot study from Melbourne looked at 18 young women with cancer or auto immune disease due to receive cyclophosphamide therapy. Sarah Maxwell spoke withKate Sternand heard more about the study.
Tags
Related Episodes
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers
“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i